Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Enhertu
Biotech
Boehringer, Bayer advance lung cancer meds toward Enhertu battle
BI's zongertinib and Bayer’s BAY 2927088 elicited objective response rates of 66.7% and 72.1% in their respective phase 1b and phase 1/2 trials.
Darren Incorvaia
Sep 9, 2024 4:43pm
AstraZeneca places next ADC bet on in-house pipeline
Feb 21, 2024 8:00am
Jazz auditioning for new bandmates in hot M&A market
Jun 6, 2023 9:35am
Eisai inks Bliss ADC deal to challenge AstraZeneca blockbuster
May 8, 2023 8:55am
BioNTech pays $170M to add would-be Enhertu rival to pipeline
Apr 3, 2023 9:15am
Roche nets FDA approval for HER2-low breast cancer test
Oct 5, 2022 11:30am
